The effect of additional topical cyclosporine or vitamin A on the ocular surface during antiglaucoma medication administration

Ophthalmic Research

Volumn 48, Issue 3, 2012, Pages 139-145

  Cho, Hyun Kyung ^a   Park, Myoung Hee ^a   Moon, Jung Il ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Adverse ocular surface change; Multiple antiglaucoma drugs; Topical cyclosporine; Topical vitamin A

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; DORZOLAMIDE; RETINOL; RYSMON TG; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNCLASSIFIED DRUG; VIVA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUNCTIVAL BIOPSY; CONTROLLED STUDY; CYTOLOGY; EXPERIMENTAL RABBIT; GLAUCOMA; MALE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CONJUNCTIVA; CONJUNCTIVAL DISEASES; CYCLOSPORINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GOBLET CELLS; IMMUNOSUPPRESSIVE AGENTS; MALE; OPHTHALMIC SOLUTIONS; RABBITS; TIMOLOL; VITAMIN A; VITAMINS;

EID: 84860862046     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000334248     Document Type: Article

References (28)

1. Chen PP: Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003; 110: 726-733. (Pubitemid 36520071)
2. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP, Butterfield LC, Gray DT: The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105: 2099-2104. (Pubitemid 30211780)
3. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713, discussion 829-830. (Pubitemid 34620348)
4. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279. (Pubitemid 36105431)
5. Turaçli E, Budak K, Kaur A, Mizrak B, Ekinci C: The effects of long-term topical glaucoma medication on conjunctival impression cytology Int Ophthalmol 1997; 21: 27-33. (Pubitemid 27382075)
6. Arici MK, Arici DS, Topalkara A, Güler C: Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Experiment Ophthalmol 2000; 28: 113-117. (Pubitemid 30458440)
7. Costagliola C, Prete AD, Incorvaia C, Fusco R, Parmeggiani F, Di Giovanni A: Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol 2001; 239: 809-814. (Pubitemid 33114932)
8. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F: Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004; 111: 2186-2192. (Pubitemid 39575587)
9. Kim EC, Choi JS, Joo CK: A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 2009; 147: 206-213.e3.
10. Wilson SE, Perry HD: Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114: 76-79. (Pubitemid 46014291)
11. Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpenn JR, Greenman HE, Savage HE: Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 2008; 126: 1046-1050.
12. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME: Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 2008; 27: 64-69.
13. Brown MM, Brown GC, Brown HC, Peet J, Roth Z: Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 2009; 127: 146-152.
14. Barber LD, Pflugfelder SC, Tauber J, Foulks GN: Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology years. Ophthalmology 2005; 112: 1790-1794. (Pubitemid 41400017)
15. Kobayashi TK, Tsubota K, Takamura E, Sawa M, Ohashi Y, Usui M: Effect of retinol palmitate as a treatment for dry eye:a cytological evaluation. Ophthalmologica 1997; 211: 358-361. (Pubitemid 27431894)
16. Singh R, Joseph A, Umapathy T, Tint NL, Dua HS: Impression cytology of the ocular surface. Br J Ophthalmol 2005; 89: 1655-1659. (Pubitemid 41729915)
17. Nelson JD, Havener VR, Cameron JD: Cellulose acetate impression on the ocular surface in dry eye states. Arch Ophthalmol 1983; 101: 1869-1972.
18. Broadway DC, Grierson I, O'Brien C, Hitchings RA: Adverse effects of topical antiglaucoma medication. 2. The outcome of filtration surgery. Arch Ophthalmol 1994; 112: 1446-1454. (Pubitemid 24350507)
19. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA: The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990; 108: 1543-1548. (Pubitemid 20377540)
20. Richter CU, Shingleton BJ, Bellows AR, Hutchinson BT, O'Connor T, Brill I: The development of encapsulated filtering blebs. Ophthalmology 1988; 95: 1163-1168.
21. Turaçli E, Budak K, Kaur A, Mizrak B, Ekinci C: The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol 1997; 21: 27-33. (Pubitemid 27382075)
22. Herreras JM, Pastor JC, Calonge M, Asensio VM: Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992; 99: 1082-1088.
23. Selek H, Unlü N, Orhan M, Irkeç M: Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol 2000; 10: 121-127. (Pubitemid 30439110)
24. Murphy PT, Sivakumaran M, Fahy G, Hutchinson RM: Successful use of topical retinoic acid in severe dry eye due to chron -ic graft-versus-host disease. Bone Marrow Transplant 1996; 18: 641-642. (Pubitemid 26316017)
25. Herbort CP, Weissman SS, Ostler HB, Cevallos A, Char DH: Ocular surface keratinization as a predictor of response to topical retinoic acid therapy. Arch Ophthalmol 1989; 107: 1275-1276. (Pubitemid 19229064)
26. Maumenee AE, Stark WJ, Maumenee IH, Jensen AD, Green WR: Topical retinoid treatment for various dry eye disorders. Ophthalmology 1989; 96: 730.
27. Tseng SC: Topical retinoid treatment for dry eye disorders. Trans Ophthalmol Soc UK 1985; 104: 489-495. (Pubitemid 15061313)
28. Pflugfelder SC. Integrating Restasis into the management of dry eye. Int Ophthalmol Clin. Int Ophthalmol Clin 2006; 46: 101-103 (Pubitemid 44632213)